Similarly a peptide domain of betaglycan called p144 and soluble betaglycan have been tested in multiple cancer types as an anti-TGF-β treatment strategy that decreases tumor growth, angiogenesis, metastasis, and augments immunotherapy [99–106]. Here, TGFB1 is linked to neoplasm.